The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the ...

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...

The Swedish pharma company Orexo and biotech firm Abera Bioscience announced today that they have joined forces to develop ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...

The Swiss aseptic fill-finish manufacturing specialist Baccinex has become the latest in a string of acquisitions by the ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US.

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks. The U.S. biotech company Amgen announced this week that its investigational drug ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US.